Results 1 to 10 of about 139,370 (300)

Antiplatelet Therapy in Heart Disease [PDF]

Reviews in Cardiovascular Medicine
Antiplatelet therapy plays a pivotal role in the management of atherosclerotic cardiovascular diseases, providing critical protection against thrombotic complications.
Nil Ozyuncu
doaj   +2 more sources

Precision antiplatelet therapy

Research and Practice in Thrombosis and Haemostasis, 2023
A State of the Art lecture titled "Personalizing Antiplatelet Therapy Based on Platelet Turnover and Metabolic Phenotype" was presented by Bianca Rocca at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. Increased variability in drug response may be associated with serious, mechanism-based and off-target side effects ...
Rocca, Bianca, Patrono, Carlo
openaire   +2 more sources

Bleeding and thrombosis outcomes in hospitalised COVID-19 patients on low-molecular-weight heparin and antiplatelet therapy

South African Medical Journal, 2022
Background. An increased incidence of thromboembolic events in hospitalised COVID‐19 patients has been demonstrated despite the use of low‐molecular‐weight heparin (LMWH).
V Pillay-Fuentes Lorente, R van Rensburg, M S Moolla, M McCaul, A Parker, J Taljaard, H Reuter, E H Decloedt   +7 more
doaj   +1 more source

Comparison of the continuation and discontinuation of perioperative antiplatelet therapy in laparoscopic surgery for colorectal cancer: A retrospective, multicenter, observational study (YCOG 1603)

Annals of Gastroenterological Surgery, 2021
Aim The present study aimed to examine the effect of continuing antiplatelet therapy in the perioperative period for patients undergoing laparoscopic resection for colorectal cancer who had received preoperative antiplatelet therapy.
Hiroki Ohya, Jun Watanabe, Yusuke Suwa, Kazuya Nakagawa, Hirokazu Suwa, Mayumi Ozawa, Atsushi Ishibe, Chikara Kunisaki, Itaru Endo   +8 more
doaj   +1 more source

DENTAL MANAGEMENT AND BLEEDING COMPLICATIONS OF PATIENTS ON LONG-TERM ORAL ANTIPLATELET THERAPY. REVIEW OF EXISTING STUDIES AND GUIDELINES. [PDF]

Journal of IMAB, 2013
Antiplatelet drugs are currently widely used in primary and especially secondary prevention of cardiovascular events. Dental management of patients on antiplatelet therapy is still not clearly defined: the discontinuation of antiplatelet therapy ...
Atanaska Dinkova, Donka G. Kirova, Delyan Delev   +2 more
doaj   +1 more source

Antiplatelet therapy and long-term mortality in patients with myocardial injury after non-cardiac surgery

Open Heart, 2023
Backgrounds Myocardial injury after non-cardiac surgery (MINS) has recently been accepted as a common complication associated with increased mortality. However, little is known about the treatment of MINS.
Seung-Hwa Lee, Seung Woo Park, Jihoon Kim, Sang-Chol Lee, Jungchan Park, Ji-hye Kwon, Kwangmo Yang, Jong Hwan Lee, Jeong Jin Min   +8 more
doaj   +1 more source

Effects of Periprocedural Tirofiban vs. Oral Antiplatelet Drug Therapy on Posterior Circulation Infarction in Patients With Acute Intracranial Atherosclerosis-Related Vertebrobasilar Artery Occlusion

Frontiers in Neurology, 2020
Background and purpose: Tirofiban and oral antiplatelet drugs can be used to inhibit reocclusion and restore microvascular reperfusion during endovascular treatment (EVT).
Xuan Sun, Huijun Zhang, Xu Tong, Feng Gao, Gaoting Ma, Zhongrong Miao   +5 more
doaj   +1 more source

Artificial Intelligence and Neurosurgery: Tracking Antiplatelet Response Patterns for Endovascular Intervention

Medicina, 2023
Platelets play a critical role in blood clotting and the development of arterial blockages. Antiplatelet therapy is vital for preventing recurring events in conditions like coronary artery disease and strokes.
Khushi Saigal, Anmol Bharat Patel, Brandon Lucke-Wold   +2 more
doaj   +1 more source

Oesophageal submucosal hematoma after flow diverter embolization with favourable outcome treated by discontinuing postoperative antiplatelet therapy for only three days: a case report

JA Clinical Reports, 2019
Background Oesophageal submucosal hematoma is a rare perioperative complication. When this complication develops after endovascular surgery, which requires postoperative antiplatelet therapy, whether to stop antiplatelet therapy or not is controversial ...
Eriko Takeyama, Aiko Wada, Eizo Amano, Hiromi Shibuya   +3 more
doaj   +1 more source

The Risk of Perioperative Bleeding in Patients with Dual Antiplatelet Therapy

Український журнал серцево-судинної хірургії, 2021
Background. Patients with dual antiplatelet therapy have high risk of perioperative bleeding. In this article we evaluated the risk of bleeding in patients whose antiplatelet therapy had not been canceled before coronary artery bypass grafting (CABG).
Taras M. Domanskyy, Artur V. Gabriyelyan, Oleg V. Beregovoy, Stanislav I. Filianin, Svitlana S. Moshta   +4 more
doaj   +1 more source